Cellular and T cell engager Immunotherapy
Efficacy of linvoseltamab in prespecified high risk subgroups of patients with relapsed/refractory multiple myeloma: Results from LINKER-MM1
Attaya Suvannasankha, MD
Associate Professor
Indiana University Simon Cancer Center and Roudebush VAMC, Indianapolis, IN, USA, United States